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ABSTRACT
Adipose tissue functions as a secretory organ. Adipocyte-derived All and
prostaglandins are involved in promotion of adipocyte hyperplasia through enhancement of
preadipocyte differentiation as well as adipocyte hypertrophy. All was proposed to regulate
adipocyte differentiation in part via prostacyclin. The peptide hormone leptin encoded by
the ob gene is produced primarily by adipocytes and is believed to be the signal indicating
the level of adiposity. We have previously demonstrated that All increases ob gene
transcription in adipocytes. In this study, we have examined mechanisms of All effect on
leptin secretion in adipocytes. All at physiological concentrations significantly increased
leptin secretion in human adipose tissue and 3T3-Ll adipocytes in a dose and time
response manner. Consistently, 6-keto PGF1a (a stable degradation product of PGii) and
PGE2 secretions were also significantly stimulated by physiological doses of AIL Inhibitors
of prostaglandin biosynthesis, namely indomethacin and aspirin significantly blocked basal
as well as All-induced prostaglandin synthesis. However, inhibition of prostaglandin
synthesis by these inhibitors did not modify All-induced leptin secretion. Consequently,
these findings demonstrate that All regulation of leptin secretion from adipocytes is
independent of prostaglandin.
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PART I

INTRODUCTION

Obesity is a complex multifactorial disease characterized by interactions of
genetic predisposition with physiological and behavioral alterations and it is associated
with a number of pathological disorders including cardiovascular disease, non-insulin
dependent diabetes, and hypertension. Several studies have recently investigated the role of
fat cells in the development of human obesity. Beyond its role in energy storage, adipose
tissue also participates actively in energy regulation and lipid homeostasis via production
of biologically active compounds. Adipose tissue has been shown to be a potential site for
the local synthesis of All that is the main effector peptide of the RAS (Renin Angiotensin
System) and plays an important role in the regulation of vascular homeostasis. Recent
studies on the role of All in adipocytes have illustrated that All increases fat mass and lipid
storage as well as transcription of ob gene, a marker of adiposity. The ob gene product
leptin binds to its receptors in the hypothalamus and plays an important role in the
regulation of food intake and energy metabolism in rodents and humans. Adipocytes also
secrete prostaglandin, which has been shown to mediate All effect on adipocyte
hyperplasia. Therefore, the purpose of this study is to investigate the effect of All on lepin
secretion as well as to determine the role of prostaglandins as possible mediators of this
effect. This investigation may offer means to develop pharmacological and therapeutic
strategies for treatment and prevention of obesity.
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RESEARCH OBJECTIVES
The objective of this research is to determine whether All regulates leptin secretion in
adipocytes via a prostaglandin-mediated mechanism. This objective will be examined by
addressing the following specific aims.
1) Determine All effect on leptin secretion in human adipose tissue as well as 3T3-L 1
adipose cells.
2) Determine All effect on prostaglandin secretion in 3T3-Ll adipose cells.
3) Investigate the effect of prostaglandin biosynthesis on All regulation of leptin
secretion in 3T3-Ll adipose cells.

3

PART II

REVIEW OF THE LITERATURE

4

I. ADIPOSE TISSUE: AN ENDOCRINE AND PARACRINE ORGAN

A. Adipose tissue: a secretory organ
Adipocytes are highly specialized cells that play critical roles in energy regulation as well as
homeostasis. Their primary role is to store energy in the form of triglycerides during periods of
nutritional abundance and to release it in the form of free fatty acids at time of nutritional
deprivation (1). Along with their active role in regulating energy balance, adipocytes behave as
endocrine as well as paracrine/autocrine cells via producing and releasing many different
bioactive compounds (2). Secretory products of adipocytes including leptin, angiotensinogen
(AGT), prostaglandins (PGs), cytokines such as tumor necrosis factor a (TNF-a) and
interleukin (IL-6), non-esterified fatty acids (NEFA), acylation stimulating protein (ASP) and
others are involved in immunological responses, cardiovascular function and appetite
regulation (4-11). Thus, adipose tissue plays more dynamic roles than previously recognized in
physiological mechanisms including the autoregulation of adipocyte growth and development.
However, abnormal quantitative increases in mass of adipose tissue associated with obesity
give rise to quantitative and qualitative alterations in adipose tissue endocrine responses,
leading to maladaptive effects predisposing to metabolic disease (2).

B. Adipocyte differentiation
Adipose tissue growth is accompanied by an increase in adipocyte size (hypertrophy) and
the formation of new adipocytes from precursor cells (hyperplasia) (113). Adipocyte
differentiation is a complex process characterized by many changes in cell morphology,
hormone sensitivity and expression of adipose-specific genes controlling lipogenesis and
lipolysis (14-16, 28). Many hormones, growth factors, cytokines and arachidonate metabolites
modulate adipogenic processes (17-19, 21, 23). Among these hormones, glucocorticoids
5

increase differentiation of preadipocytes by transcriptional repression ofpref 1, which is an
epidermal growth factor-like domain-containing transmembrane protein with anti-adipogenic
function that is highly expressed in 3T3-Ll preadipocytes (178). The cytokine TNF-a and
PGF2a exert inhibitory effects on adipocyte differentiation (20-2 1). In contrast, differentiation
of preadipocyte cell lines such as 3T3-Ll is induced by continuous exposure of
pharmacological doses of insulin and physiologic doses of insulin-like growth factor 1 (22-23).
Moreover, angiotensin II (All) and arachidonic acid metabolites such as PGh promote the
conversion of fibroblasts to functionally mature adipocytes in Ob 1771 adipose cells (24-25). In
addition, dietary fatty acids induce differentiation of these cells by activating peroxisome
proliferator-activated receptor y (PPARy) (26).
Two classes of transcription factors, CCAAT/enhancer binding protein family (C/EBP
family) and PPAR y play significant roles as positive mediators of adipogenesis (27-28, 41).
PPARy is one member of the PPAR subfamily of ligand-dependent nuclear hormone receptors
and its gene generates two isoforms PPARyl and y2 through alternative splicing (29). The
functional domains of PPARy are composed of five regions: the transactivation function
domain, DNA binding domain, receptor dimerization function domain and ligand binding
domain (30). While PP ARyl is expressed at low levels in several tissues such as large
intestine, kidney and liver, PPARy2 is abundantly and specifically expressed in adipocytes
(31 ). PPARy plays a central role in regulating fat-specific gene expression such as an
adipocyte-specific fatty acid binding protein (aP2), phosphoenolpyruvate carboxykinase
(PEPCK), lipoprotein lipase (LPL), glucose transporters (GLUT4) and leptin by binding to
DNA sequences termed PPAR response elements as a heterodimer with retinoid X receptor
6

(RXRa) (32-34). Further, PPARy is activated by various synthetic and naturally-occurring
substances including antidiabetic thiazolidinediones, polyunsaturated fatty acids, 15-deoxy
delta prostaglandin J2 and lipoxygenase products such as 8-(S)-hydroxyeicosatetraenoic acid
(HETE), leading to adipocyte differentiation (19, 35-38,130). Recently, non-steroidal anti
inflammatory drugs (NSAIDs) classified as cyclooxgenase blockers, such as indomethacin and
ibuprofen, also have been shown to act as PPARy agonists (39). However, the identities of
endogenous ligands for PPARy and characteristics of their production in vivo have not been
established.
The C/EBP family also plays an important role as an adipogenic factor, in part by
modulating the expression and activity of PPAR y. Hormonal induction of C/EBP p and 8
stimulates PPARy expression ( 40). C/EBPa, which may induce continued expression of
PPARy, binds to the promoters of fat cell genes leading to maintenance of the fully
differentiated state (41-42).

II. THE ROLE OF ANGIOTENSIN II IN ADIPOCYTE GROWTH AND DEVELOPMENT

A. Classic Renin-Angiotensin system (RAS)
The renin-angiotensin system (RAS) plays a vital role in the regulation of blood pressure as
well as fluid and electrolyte balance (45). The RAS consists of several components, which
include angiotensinogen (AGT), renin, angiotensin-converting enzyme (ACE), and All
receptors. The RAS produces the vasoactive peptide hormone AIL The components of classic
RAS are synthesized in the liver, kidney and endothelium (43). In addition, local synthesis of
components of the RAS (nonclassic RAS) has been found, mostly in organs involved in
7

cardiovascular regulation including the heart, peripheral blood vessels, brain, adrenals as well
as adipocytes (46-47, 51, 57).
B. Renin-Angiotensin system (RAS) in adipose tissue

AGT expression has been identified in murine adipose cell lines and rodent adipose tissue
(48-49). Human adipose tissue also expresses AGT mRNA, ACE mRNA, and the renin gene
(50-51, 68). In brown adipose tissue from rodents, local production of AGT and renin activities
have been described (52-53). All receptor type 1 (ATl) is expressed in adipose cells from rats
as well as in human preadipocytes and adipocytes, and All receptor type 2 (AT2) is expressed
in murine, human and mouse adipose cells (54-56, 58-59). Additionally, transcripts for
cathepsin D and cathepsin G, enzyme components of the nonrenin-angiotensin system
(NRAS), are detectable in human adipose tissue by polymerase chain reaction (PCR) (60).
Collectively, these findings strongly suggest that adipose tissue is an important peripheral site
containing regulatory components of the local RAS, providing insights into the significant
function of adipocyte-derived All in adipocyte metabolism and cellularity.
C. Effect ofAll on adipogenesis
All, which is the primary effector peptide of RAS is metabolized rapidly by a number of
peptidases and thus has a relatively short half-life of approximately 15s (61). In spite of its
short half-life, All functions as a modulator of vascular tone (45). In addition to its role in
vasoconstriction, early investigations on the role of peripheral RAS have illustrated that All
has hypertrophic and hyperplastic activities in vitro leading to growth and development of
nonclassical RAS in tissues such as brain and fetal tissue (63-64). This suggests the possibility
that the AGT produced in adipose tissue itself may influence adipogenesis and play a role in
the pathogenesis of obesity. In light of a potential physiological role for All in regulating
8

adiposity, AGT expression is differentiation-dependent (12). Consistently, Harp and
DiGirolamo has illustrated a positive relationship between expression of AGT mRNA and
protein, the only known precursor to All, and relative rates of adipocyte growth in rats (65).
Further, under conditions of genetic obesity (ob/ob and db/db), AGT synthesis by adipocytes is
increased compared with lean controls, suggesting a potential link between obesity and
functional local RAS in adipose tissue (67). Consistent with this concept, AGT expression in
adipocytes is reduced in states of fasting and enhanced in overfeeding and AGT expression is
stimulated by a high fat diet concomitant with enlargement of fat mass (66-67). In addition,
while P-adrenergic receptor agonist decreases AGT expression in 3T3-Ll adipose cells, insulin
increases AGT expression (68). However, decreased AT mRNA and secretion of All by low
concentrations of insulin were observed in cultured Ohl 771 and 3T3-F442A adipose cells (13).
Similarly, glucocorticoids upregulate AGT gene expression in Ob1771 cells in a dose
dependent manner, in tum leading to growth of adipose tissue (69). Epidemiological studies
have shown a tight correlation between accumulation of intra-abdominal fat and hypertension
(70-71, 44). A significant correlation between plasma AGT level, blood pressure and the ob
gene product leptin, which is proposed as an endogenous marker of adiposity was reported
(72). However, the contribution of adipose-derived All to pathophysiological hypertension is
not well understood. Taken together, these findings suggest that adipose tissue hypertrophy is
accompanied by an increased activity of the tissue RAS. Along with its function in adipose
tissue development, All may also contribute to the association between hypertension and
obesity.
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D. Effect AII on function of brown adipose tissue
A previous study has demonstrated that rat brown adipose tissue (BAT), which plays a
critical role in cold-induced thermo genesis, is capable of producing All (176). The
thermogenic function of BAT is mediated primarily by norepinephrine (NE) released from
sympathetic nerves densely innervating this tissue (82). Accordingly, recent research has
reported the potential role of All in BAT function. The study of Cassis has demonstrated that
production of endogenous All is increased in rat intrascapular BAT (ISBAT) during cold
acclimation and All-induced [3H] NE release is enhanced from ISBAT in response to cold,
suggesting a potential role of All in stimulating thermogenesis in BAT (73). In subsequent
studies, decreased content of All in ISBAT of young obese Zucker rats was observed and AII
mediated neuronal uptake of [3 H] NE in ISBAT was also decreased in both young and adult
obese rats (74). This finding suggests that alterations of All production and function in the
obese animal model appear to decrease energy expenditure associated with BAT
thermogenesis, consequently contributing to development of obesity.

E. Mechanisms ofAII effects on adipose tissue
AII exerts its action via at least two distinct receptors subclassified as AT l and AT2 (Table
1) (75). The recent study has demonstrated that treatment of losartan, an ATl receptor specific
antagonist, significantly inhibits the age-dependent increase in rat adipocyte size (76). Further,
the studies of Darimont et al have illustrated by using a coculture of preadipocytes and
adipocytes, that All promotes adipocyte differentiation by stimulating release of prostacyclin
(PGii) from mature fat cells, which has an autocrine adipogenic effect in vitro through an AT2receptor mediated mechanism (77). In addition, AII enhances expressions of PGHS-1
(prostaglandin endoperoxide synthase) and PGHS-2 mRNA in mature adipocytes, thus
10

Table 1 . Characteristics of Angiotensin II receptor subtypes

Receptors
AT l
Selective antagonists

G-protein coupled
Signal transduction

Species

Losartan (DuP 753)
SK&F 1 08566
L- 1 58809
YES (Gi , Gq)
t IP 3 and [Ca2+]
.J.. cAMP
Human
Bovine
Rat (AT 1A, AT rn)
Mouse

AT2
PD 1 23 1 77
PD 1 233 1 9
WL 1 9 (PD 1 2 1 98 1 )
CGP 42 1 1 2A
YES
.J.. cGMP
.J.. Phosphotyrosin
Phosphatase
Human
3 T3-L I adipose cells
Ob 1 77 1 adipose cells
Rat
Mouse

promoting prostaglandin (PG) production (78). Interestingly, All regulates lipogenesis by
increasing fatty acid synthase (FAS) and glycerol-3-phosphate dehydrogenase (GPDH)
activities as well as triglyceride storage via an AT2-dependent mechanism, concurrent with
elevated transcription rate of ob gene in 3T3-Ll and human adipose cells (79). More recently,
studies in vivo have shown that PD1 23139 (an AT2 receptor antagonist)-treated mice display
significant decreased leptin content in adipose tissue as well as decreased epididymal fat pad
mass, compared to controls (Kim et al 1 999). Collectively, these findings suggest that
adipocyte-derived All regulates secretion of leptin, which is positively correlated with adipose
mass, via possibly a PG-mediated mechanism that controls growth and development of
adipocytes.

III.LEPTIN REGULATION OF ENERGY HOMEOSTASIS
A. Obese(ob) gene and leptin : discovery and structure

The important 'role of ob gene in energy balance was originally demonstrated by the
Coleman's parabiosis (cross-circulation) experiments with ob/ob, db/db and lean mice (81).
This study indicated that a circulating factor present in the blood of wild type lean or db/db
obese mice reversed the effects of ob mutation and furthermore the db/db mice lacked ability to
respond to this factor. Ob/ob and db/db are mutant mice that have single gene mutations
residing on mouse chromosomes 6 (ob) and chromosomes 4 (db) respectively. Both mice
exhibit a reduced basal metabolic rate, hyperphagia and massive obesity (81). Importantly, the
positional cloning of this gene by Friedman's group in 1994 led to the discovery of its gene
protein product named leptin. Consistent with early parabiosis studies, it was demonstrated that
ob/ob mice produce a truncated and inactive form of leptin hormone due to a premature stop
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codon in the gene (4). Leptin is synthesized as a 167 amino acid protein primarily in adipose
tissue. Small amounts of leptin are produced by muscle, placenta and stomach and released
into the circulation after cleavage of a 21 amino acid signal peptide (83-85). It circulates in
mouse and human plasma either as free or bound to other circulatory proteins such as several
hormone receptors or soluble leptin receptors (179). Circulating leptin is transported to the
cerebrospinal fluid where it is available to bind and activate specific receptors on the
hypothalamus to regulate energy balance via interaction with its receptors (86, 91-92, 104). In
addition, Zhang et al have observed that leptin folds into a cytokine-like structure, which
includes 4 a-helices, 2 �-sheets, and a single disulfide bond between cysteines 96 and 146
(88). Consistent with leptin protein structure, the receptor for leptin protein is a single
membrane-spanning protein with structural and functional homology to the class I cytokine
receptor family (98).
B. Leptin receptors
The leptin receptor was cloned from mouse choroid plexus and the gene encoding the leptin
receptor was genetically mapped to the same 5-centimorgan interval on mouse chromosome 4
containing the db locus (90, 98). Spontaneous mutations in the leptin receptor gene in db/db
mice and fa/fa rats produce defective leptin receptors, consequently these rodents develop
severe obesity with resistance to endogenous and exogenous leptin (93-95). The leptin receptor
(Ob-R) is a member of the cytokine receptor family. Receptors of this class lack intrinsic
tyrosine kinase activity and are activated by ligand-induced receptor homo-or
heterodimerization and utilize Janus kinases (JAK) and signal transducers and activators of
transcription (STAT) family proteins to modulate transcription of target genes (96-97).
Multiple splice variants of Ob-R mRNAs encoding proteins with identical extracellular
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domains but different length intracellular domains have been detected. The short splice
variants, Ob-R (a, c and d) encode a receptor with a single transmembrane domain, a
cytoplasmic region of variable length and diminished signaling capabilities (98). One of the
shorter splice variants, Ob-Re encodes a soluble form lacking a transmembrane domain. Ob-Rb
encodes a long form of leptin receptor with. a long intracytoplasmic domain of 302 amino acids
containing several motifs known to be important for protein-protein interactions and signal
transducing activity, including both JAK interaction and STAT docking sites (96, 99-100). In
mammals, the short forms of the leptin receptor are expressed ubiquitously and found in high
amounts in the lungs, kidneys and uterus. In addition, it is highly expressed in the choroid
plexus, suggesting the possibility that this isoform mediates translocation of leptin across the
blood-brain barrier (177). The long form is found at high levels in the arcuate nucleus (ARC)
within the hypothalamus known to be important for body weight regulation, with lesser
amounts observed in peripheral tissues including liver, heart, skeletal muscle, pancreatic � cells
and brown and white adipose tissue (98, 102-103). This isoform of the receptor is proposed to
mediate leptin' s effects on body weight homeostasis by decreasing food intake and increasing
energy expenditure
Transient co-transfection studies have revealed that the long form of receptor protein is
capable of activating STAT proteins in response to ligand binding ( 100). Similarly, STAT3 and
STATS have been stimulated in COS cells by expressing Ob-R (1 15). In vivo, STAT3
activation in the hypothalamus has been detected when exogenous recombinant leptin is
administered (105). In addition, leptin induced a dose-and time-dependent increase in mitogen
activated protein kinase (MAPK) in C3Hl OTl /2 cells in parallel with increased cell number
and JAK-2 has also been activated via long form leptin receptor upon leptin stimulation
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(96,106). Recently, receptor chimera studies have indicated that the long form of the receptor
signals via homo-oligomers (107). JAK.s associated with this receptor become activated,
autophosphorylated and phosphorylate STAT proteins, which then dimerize and translocate to
the nucleus to activate transcription of target gene for weight-reducing effects of leptin
(108,115). Furthermore, recent study has demonstrated a leptin inducible inhibitor of leptin
signal transduction, SOCS-3 (suppressor of cytokine signaling) family blocks leptin-induced
activation of STAT3 in cells expressing the long form of the leptin receptor. This suggests a
potential mechanism for leptin resistance related to obesity (180). Cumulatively, these findings
suggest that the long form of leptin receptor plays a role as a signal transducing receptor in the
leptin signaling cascade. Lack of the intracellular long form of leptin in db/db mice is due to a
premature stop codon resulting from G to T substitution. Thus, receptors cloned from db/db
mice are shown to be unable to activate STAT protein (94, 97). Infalfa obese Zucker rats, a
missense point mutation (A�) results in Gln to Pro substitution in the extracellular ligand
binding domain of Ob-R, producing partial deficiency of Ob-R function (95). Consequently,
the /a-type receptors exhibit a reduced leptin-binding affinity and signal transduction.

C. Regulation of leptin expression and leptin secretion
Leptin research has shown that environmental and hormonal factors contribute to leptin
gene expression and secretion. Leptin expression is influenced by the degree of energy
restriction. In rodents and humans, leptin mRNA and plasma levels are greatly decreased after
fasting and increased by refeeding and overfeeding (109-112). This suggests that function of
leptin is involved in controlling of energy balance. Recent studies have demonstrated that
changes in leptin concentration in response to diet composition such as the high fat diet (60
energy % fat, for 7 days) correlated with changes in insulin concentration, implying that leptin
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production is positively regulated by insulin (114). Consistent with the proposed insulin
regulation of leptin, insulin administration increases ob mRNA expression as well as leptin
secretion in rat adipocytes (117). However, other studies have reported no effect of insulin on
ob expression and leptin secretion (80,116). These conflicting reports have been suggested to

result from the use of different culture model (118). Glucocorticoid stimulation of leptin gene
expression and circulating leptin levels has been shown both in vivo and in vitro studies (80,
116, 118-119). In contrast, catecholamines, by increasing intracellular cAMP levels via /h and

/JJ adrenoreceptors, suppress ob mRNA expression and leptin production (120). Furthermore,
several lines of evidence have indicated that plasma leptin levels and ob gene expression vary
in proportion to the degree of adiposity in lean and obese animals and humans, indicating a
leptin role as an"adipostat" signal (121-123, 125). Additionally, the studies of Masuzaki et al
have reported that ob mRNA levels are higher in the subcutaneous adipose tissue compared to
the omental, retroperitoneal, and mesenteric adipose tissue in the same individual. This
suggests regional differences in leptin production rates (124).
Recently, C/EBPa, which is a transcription factor regulating adipocyte differentiation,
has been identified as a transactivator of the leptin promoter through binding to a consensus
C/EBP-binding site in the proximal leptin gene promoter (126). Treatment with the antidiabetic
drug thiazolidinedione, a ligand for PPARy, decreases expression of the endogenous leptin
gene in rodent and 3T3-Ll adipocytes, suggesting that PPARy is involved in the transcriptional
regulation of the ob gene (127). Studies of Hollenberg et al have revealed that PPARy2
mediates downregulation of the leptin promoter through inhibition of C/EBPa-activated
transcription (128). Additionally, adipocyte determination differentiation dependent
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factorl /sterol regulatory element binding proteinl (ADD1 /SREBP1 ), which is regulated by
nutritional status and insulin level, has been shown to be involved in the transcriptional
regulation of the leptin gene promoter ( 1 29). These findings suggest that adipocyte
differentiation and growth is critical for modulating the ob gene expression and leptin
production.
D. Biological function of leptin in energy balance
Several studies have demonstrated that the hypothalamus is a potential site for the action of
leptin on body weight regulation (86). Injection of leptin into the lateral ventricle of ob/ob mice
( characterized by hyperphagia, increased adiposity, hyperglycemia and insulin resistance)
induces suppression of food intake and body fat (87). Similarly, after leptin was administered
intracerebroventricularly (ICV) reduced food intake and body weight were observed in diet
induced obese (DIO) and ob/ob mice as well as lean mice ( 1 32-1 33). Leptin appears to act in
maintaining energy homeostasis through the long form of the receptor in the hypothalamus. In
addition, chemical lesions of the ventromedial hypothalamus (VMH) where leptin receptors are
expressed cause overeating and severe obesity ( 1 34). Leptin was suggested to inhibit food
intake by down-regulating NPY. In agreement with this hypothesis, pre-pro-neuropeptide Y
(NPY) mRNA (a potent stimulator of food intake) in the arcuate nucleus (ARC) of the
hypothalamus was overexpressed in the genetically obese (ob/ob) and db/db mice as well as
fa/fa rats (89, 1 01 ). Leptin administration significantly lowered NPY mRNA levels in the ARC
of ob/ob mice ( 1 0 1 ). Thus, impaired leptin signaling may stimulate NPY production and
release, suggesting that leptin exerts its central effects through NPY. Furthermore, the ICV
NPY infusion induces increases in leptin production by rat adipose tissue (1 32). In addition,
the direct microinjection of NPY into the paraventricular nucleus (PVN) inhibited the
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hypophagic and thermogenic effects of centrally (ARC) administered leptin, suggesting that
leptin produced by white adipose tissue and the NPY in the ARC-PVN axis may interact in a
homeostatic loop to regulate body fat mass (62, 1 36). However, studies in NPY knockout mice
have shown that the obesity phenotype in NPY-null ob/ob mice is only partially alleviated,
implying that additional neuropeptides may be involved in the development of ob/ob
phenotype ( 1 37).
In addition to NPY, other neuropeptide are also regulated by leptin. Administration of
leptin increases corticotrophin-releasing hormone (CRH) mRNA levels in the PVN ( 1 43).
CRH administration reduces food intake and stimulates the metabolic rate in genetically obese
animals and lean controls through increasing sympathetically mediated energy expenditure
( 1 35). Leptin inhibits the orexigenic effects of galanin (GAL) and melanin-concentrating
hormone (MCH) and decreases GAL mRNA as well as MCH expression in the hypothalamus
( 1 39). When administered centrally, MCH increases food intake in a dose-dependent manner
and lowers plasma glucocorticoid levels through a mechanism involving adrenocorticotropic
hormone (ACTH) ( 1 40). Since the MCH and leptin receptor are coexpressed in the lateral
hypothalamus (LH), feeding evoked by MCH is possibly suppressed by a direct effect of leptin
signaling ( 1 41 ). Pro-opiomelanocortins (POMC) is produced in a subset of neurons in the ARC
where it is co-localized with leptin receptor (131). POMC levels in the ARC are lower in ob/ob
mice than in wild type mice and leptin increases POMC to nearly normal levels in leptin
deficient mice, suggesting POMC neurons may mediate weight-reducing effects of leptin
( 1 42). Moreover, the studies of Boston et al have demonstrated a relationship between the
leptin and POMC signaling pathways. The lethal yellow (AY/a) mouse that has a defect in
POMC signaling in the brain develops obesity. The leptin-deficient lethal yellow mice (AY/a
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ob/ob, double mutant) showed a significant restoration of leptin sensitivity after leptin

administration (144). This observation suggests that leptin functions to regulate feeding
behavior independent of POMC neurons. The specific product of POMC, a-melanocyte
stimulating hormone (a-MSH) inhibits feeding in mice and is an agonist of melanocortin-3
(MC3R) and MC4R, whose mutation is associated with development of human obesity (146149). The inhibitory effect of a-MSH on feeding is completely blocked by administration of
the MC-R antagonist SHU9119 (150). Additionally, agouti and agouti-related protein (AGRP)
are endogenous antagonists of melanocortin receptor and overexpression of AGRP results in
mice that are hyperphagic, hyperinsulinemic and obese (151-152). Leptin injection causes
reduction of AGRP mRNA in wild type as well as in leptin deficient mice (153).
In addition to control effect of leptin, peripheral effects of leptin on body weight have also
been reported (145, 156). Leptin directly inhibits triglyceride and free fatty acid formation in
both adipocytes and nonadipocytes ( e.g. liver, pancreas and skeletal muscle) by reducing
acetyl-CoA carboxylase (ACC) activity and increasing lipid oxidation.
Cumulatively, leptin modulates not only neuropeptide/neuromodulator levels in most
hypothalamic feeding centers through direct or possible indirect manners but also peripheral
lipid metabolism to regulate energy balance and adiposity.
E. Leptin and obesity

Obesity is most likely a polygenic disease characterized by interactions between genetic
and environmental factor (154). The most common complications of obesity include insulin
resistance, type II diabetes mellitus and hypertension. The epidemic of obesity probably results
from increasingly sedentary lifestyles and easy availability of palatable, high fat foods.
Recently, candidate genes such as agouti, tubby, leptin and leptin receptor associated with
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obesity have been identified and also mutations of genes which favor excess body fat have
been characterized in these animal models (162). The vast majority of obese individuals exhibit
elevated circulating leptin levels and appear to be leptin resistant similar to the syndrome of
db/db obese animal models, suggesting that human ob mutations are extremely rare (122, 1 55).

Leptin resistance in human obesity has been suggested to be associated with impaired transport
of leptin across the blood-brain barrier in the hypothalamus and impaired leptin signal
pathways (100,155). Only a few mutations in the ob gene and receptors have been associated
with human obesity. A homozygous frame-shift mutation involving the deletion of a single
guanine nucleotide in codon 133 of the gene for leptin was found in two cousins born from
extended family (157). Both children exhibit marked hyp erphagia, excessive weight gains in
early life and severe obesity. Another leptin missense mutation was found in a highly
consanguineous extended Turkish pedigree to be associated with low plasma leptin,
hyperphagia, hypogonadism, hyperglycemia and morbid obesity (158). Moreover, a
homozygous mutation in the human leptin receptor gene results in a truncated leptin receptor
lacking both transmembrane and intracellular domains and is associated with early-onset
morbid obesity, reduced growth hormone secretion as well as no pubertal development (160).
More recently, cohort studies have shown that daily subcutaneous recombinant leptin injection
in both lean and obese subjects reduced body weight and fat mass in a dose-response manner,
including in some obese subjects with elevated endogenous serum leptin concentration (161).
Also, injection of recombinant leptin has induced a sustained reduction in weight,
predominantly as a result of a loss of fat in a nine-year-old patient with congenital leptin
deficiency (163). Consequently, leptin as well as its agonists and antagonists are emerging as
novel therapeutic targets in effective drug development and strategies in treatment of obesity.
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IV. EFFECTS OF ARACHIDONATE METABOLITES ON ADIPOGENESIS

A. Arachidonate metabolites: pathways of biosynthesis
Among foods commonly consumed in the American diet, meat (chicken thigh) and eggs
are good sources of arachidonate (181 ). The formation of arachidonate (20:4 n-6) is a process
involving the elongation and desaturation of dietary linoleic acid (18:2 n-6) or direct
consumption of arachidonate. Arachidonate is found in cells with relatively abundant amounts
but almost exclusively incorporated at the sn-2 position of membrane phospholipid (164).
Arachidonate from phospholipids is released by the action of hormone-regulated
phospholipases (165). Free, arachidonate is processed by cyclooxygenases (COXs),
lipoxygenases or cytochrome p450 oxygenases to the various physiologically important
eicosanoids (Fig.I ). Two COX isoforms have been identified and are referred to as COX-1
and COX-2. Both convert arachidonate to prostaglandin G2 (PGG2 ). PGG2 is subsequently
reduced to prostaglandin H2 (PGH2 ) by the peroxidase activity and then PGH2 is transformed
by a range of enzymes and nonenzymatic mechanisms into biologically active prostanoid
products such as PGE2 , PGii, PGF2a, PGD2 and TXA2 (166). The COX-1 activity is
constitutively present in most cell types at a constant level, whereas COX-2 is rapidly induced
only after exposure of cells to hormones, growth factors, mitogenic and inflammatory stimuli,
cytokines such as interleukin-I or 2 and tumor promoters (168). COX-1 is responsible for the
biosynthesis of PGs in the gastric mucosa and in the kidney, implying a role for COX-1 in
gastric and renal homeostasis (169). In contrast, COX-2 induces production of PGs at
inflammatory sites and during pain and thus COX-2-derived PGs play a role as inflammatory
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mediators in the injured tissue (169). Additionally, COX-2 expression is markedly enhanced
in various cancer cells, indicating that this enzyme is also involved in carcinogenesis (169).
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and indomethacin inhibit
both COX-1 and COX-2 to different extents and compete with arachidonate for binding to the
COX active site (171). These compounds exert effective anti-inflammatory actions but also
unwanted side effects such as ulcerogenesis (169). NSAIDs can be classified into three groups
based on their binding kinetics with the COXs. Class I compounds are simple competitive
inhibitors which include ibuprofen and piroxicam. Class II compounds include indomethacin,
flurbiprofen and meclofenamate, which bind to the COXs leading to an initial EI (enzyme and
inhibitor) complex, but this EI complex slowly rearranges to an EI* complex from which the
inhibitors dissociate very slowly (minutes to hours). Thus, these are known as time-dependent
and reversible inhibitors. Aspirin is one of the class III inhibitors, which are competitive,
time-dependent and irreversibly and covalently modify COXs. It acetylates a serine residue
positioned in the arachidonate-binding channel, thereby blocking the binding of the fatty acid
substrate to the active site for its oxygenation and also exhibits greater potency (10 to 100
times) against COX- 1 than against COX-2 (172).
B. Role of arachidonate metabolites in adipogenesis
Arachidonate and its oxidized derivatives have been known as important mediators of
many physiological and pathophysiological processes. Furthermore, several studies have
demonstrated that arachidonate metabolites modulate positively or negatively differentiation
and maturation of adipose tissue (37). Prostaglandin E2 (PGE2) and prostacyclin (PGh) have
been described as two major PGs produced from rodent and human adipocytes (6, 159). In
addition, low levels of prostaglandin F2a (PGF2a) released from adipocytes have been reported
23

(6). Recently, the studies of Vassaux et al have shown that PGE2 negatively modulates cAMP
production and thus lipolysis in rat and human adipocytes via interaction with its specific
receptors (25). This suggests that the antilipolytic effect of PGE2 contributes to hypertrophic
development of adipose tissue (25). Conversely, PGiz and carbaprostacyclin (cPGI2), its stable
analogue, are proposed to act as adipogenic-hyperplastic effectors. Differentiation of Ohl 771
preadipocytes is stimulated by cPGlz, This effect is mediated by increased cAMP production
and free intracellular calcium release, leading to an elevation of fat cell number from
predominant preadipocytes (3,170). More recently, studies by Hertz have demonstrated that
cPGiz activates the three known mammalian PPARs (a,8 and y), indicating that its ability to
1 1
promote differentiation may be mediated by PPARs (175). Another PG, 15-deoxy-� 2· 4-

prostaglandin J2 (PGJ2) is an important ligand for PPARy, an adipogenic transcription factor,
that induces adipogenesis of cultured fibroblasts (35). In addition, prostaglandin D2 (PGD2)
derivatives have been reported to be efficacious activators of both PPARa and PPARy (130).
In contrast, PGF2a has been shown to inhibit the differentiation of 3T3-Ll and rat
preadipocytes (173). In murine 3T3-Ll cells, inhibition of differentiation by PGF2a is
mediated by specific binding to a FP receptor that activates phospholipase C, resulting in the
formation of inositol phosphate and mobilization of intracellular calcium. Moreover, FP
receptor stimulation causes activation of calcium/calmodulin-dependent protein kinase
(CaMK) and an increase in DNA synthesis without cell proliferation. Addition of CaMK
inhibitor KN-62 blocks the inhibitory effects of PGF2a in the presence of the FP receptor
agonist. In combination, this suggests that CaMK and augmentation of DNA synthesis are
responsible for PGF2a-mediated inhibition of differentiation (20,138,167). Further, 8-(S)24

hydroxyeicosatetraenoic acid (HETE), a product of the lipoxygenase pathway, has been
reported as an activator of PPARy2 leading to differentiation of3T3-Ll preadipocytes (19).
Interestingly, recent research has investigated effects of inhibitors of PG biosynthesis on
adipocyte differentiation. The studies of Lehmann et al have addressed the mechanism of
stimulation of differentiation by indomethacin. At low concentrations, indomethacin exhibits
its inhibitory effects on COXs, but at high concentrations, it directly binds and activates
PPARa and y and thus induces the differentiation of C3Hl0Tl/2 fibroblasts, suggesting that
PPARy plays an important role as a mediator in indomethacin-induced adipogenesis (39).
Furthermore, the role of indomethacin in ob gene expression, a known marker of terminal
differentiation, has been examined by using differentiating and fully differentiated 3T3-L1
adipocytes. Indomethacin exerts inhibitory effects on leptin secretion at the concentration at
which it activates PPARy in differentiating and fully differentiated adipocytes, implying that
indomethacin-induced PPARy activation may be involved in initial-stage rather than the later
stage of differentiation (174). Consequently, arachidonate metabolites produced locally by
adipocytes participate in adipocyte growth and development via interactions with not only
their cell surface receptors but also nuclear receptors and thus may act as important
paracrine/autocrine effectors in adipogenesis.
In summary, adipose tissue secretes various bioactive molecules including All, leptin
and prostaglandins. Available data indicate that All increases triglyceride content and ob
gene transcription in adipocytes. In addition, All modulates adipocyte differentiation via a
prostaglandin-dependent mechanism. The objective of this thesis is to investigate whether
All modulates leptin secretion via a prostaglandin-dependent mechanism.
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ANGIOTENISN II INCREASES LEPTIN SECRETION IN ADIPOCYTES VIA A
PROSTAGLANDIN-INDEPENDENT MECHANISM
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I. ABSTRACT
We previously reported that All increases fatty acid synthesis and triglyceride storage
in adipose tissue. Several studies have demonstrated that triglyceride stores or adiposity
correlate significantly with the amount of circulating leptin. All has been shown to
increase adipocyte differentiation and growth by promoting prostaglandin production in
OB1771 cell line. The purpose of this study was to determine whether All regulates
leptin secretion via a prostaglandin-dependent mechanism in adipocytes. Physiological
doses of All significantly increased leptin secretion by 3T3-Ll adipocytes and human
adipose tissue in a dose-and time-dependent manner. Elevation of prostaglandin
secretions was elicited at physiological concentrations of All (p<0.05). Secretions of 6keto PGF 1 a, a stable derivative of PGI2, and prostaglandin E2 were significantly induced
by physiological concentrations of All in a time-response fashion (p<0.05). Inhibition of
prostaglandin synthesis by indomethacin and aspirin significantly suppressed basal as
well as All-induced prostaglandin levels, but did not significantly affect basal and All
induced leptin secretions. In conclusion, regulation of leptin secretion by All in
adipocytes is not modulated by a prostaglandin-dependent mechanism.

II. INTRODUCTION
Angiotensin II (All) is well known as a vasoactive peptide hormone that regulates
blood pressure as well as fluid and electrolyte balance (1). All is classically synthesized
by two enzymatic steps in which renin and angiotensin converting enzyme (ACE) cleave
the precursor angiotensinogen produced by the liver (1). Local synthesis of RAS has been
found in liver, kidney and various tissues including adipose tissue (2). In brain and
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kidney, RAS has been shown to control morphological development (29, 34). Adipose
tissue represents the potentially largest sources ofthe angiotensinogen (AGT), especially
in obese patients (5-6, 31,13). Angiotensinogen (AGT) mRNA expression in mouse
adipose tissue is reduced by fasting and enhanced by overfeeding (6). AGT gene
expressed in human adipose tissue is regulated nutritionally as well as hormonally,
providing important insights into the function ofadipocyte-derived All in adipocyte
metabolism (9). Data from cultured murine adipocytes indicate an adipogenic role ofAll
in adipocyte growth and development (4,12,14). Increased AGT protein synthesis in
adipocytes ofgenetic obesity models ( ob/ob and db/db) suggests a potential link between
obesity development and functional local All in adipose tissue (6). Epidemiological
studies show a tight correlation between accumulation ofintra-abdominal fat and
hypertension (10). Cumulatively, these data suggest that adipocyte hypertrophy is
accompanied by an elevated activity ofRAS. In addition to its function in adipose tissue
growth, All might contribute to obesity as well as obesity-associated hypertension,
although the contribution ofadipocyte-derived All to pathophysiological hypertension is
largely unknown.
Leptin is the protein product ofob gene cloned by Friedman 's group in 1994 and is
primarily expressed in adipose tissue (8). Leptin circulates in the blood and acts on the
central neural network that regulates weight and energy (17,19). Defects in the ob gene as
well as leptin receptor genes cause obesity in ob/ob and db/db mice and humans (rare
mutations) (8,16, 21). Most human obesity is positively correlated with elevated serum
concentrations of leptin as well as decreased sensitivity to leptin, inducing leptin
resistance (20-21, 28). Leptin administration leads to decreased food consumption and
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increased energy expenditure, both of which result in loss of adipose mass in lean, obese
and diet-induced obese (DIO) models, indicating a weight-reducing and anti-obesity
effect of leptin ( 1 8, 27). Investigations into the mechanisms of leptin (a marker of
adiposity) regulation by All may provide new insights into the development of
therapeutic approaches to treat obesity.
Previous studies from our lab have demonstrated that All activates ob gene
expression ( 1 2). In vivo data have shown that mice treated with an AT2 receptor
antagonist, PD 1 23 1 39 display significantly decreased leptin content of adipose tissue
concomitant with decreased epididymal fat pad mass (Kim et al 1 999). These results
provides additional evidence that All functions as an adipogenic factor in adipocyte
metabolism and support potential mechanisms for the effect of All on adiposity.
Mechanistically, All has been shown to enhance adipocyte differentiation by AT2 dependent generation of prostacyclin (14). Studies by Borglum et al ( 1 5) have
demonstrated that All increased expression of PGHS- 1 and PGHS-2 mRNA in mature
adipocytes leading to prostaglandin production ( 1 5). Prostacyclin and prostaglandin E2
have been shown to exert their roles as paracrine or autocrine adipogenic effectors in
adipocyte growth and development (7, 1 1, 24). However, the mechanism of All
regulation of adiposity remains under investigation.
We hypothesized that All might regulate leptin in adipocytes via a prostaglandin
mediated mechanism. We first analyzed dose and time effects of All on adiposity and
prostaglandin secretions in adipocytes, using leptin as an adiposity marker. The effects of
prostaglandin biosynthesis inhibition by indomethacin and aspirin on All regulation of
leptin in adipocytes were investigated. We confirmed the inhibitory effect of
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prostaglandin by indomethacin is independent of regulation of leptin secretion by All in
adipocytes. This study may provide evidence of a potential mechanism of All regulation
of adiposity as well as clues for All signaling pathway in adipocyte metabolism.

III.RESEARCH DESIGN AND METHODS
A. Experimental design (Fig. I)
Experiment 1 : we have demonstrated that dose and time-response study of leptin

secretion to All treatment in human adipose tissue and 3T3-L l adipose cells. We
conducted dose and time-response analyses of 6-keto PGF la and PGE2 secretions in
response to All in 3T3-Ll adipose cells only.
Human adipose tissue: Human adipose tissue was cultured in 6-well (35mm) plates in
DMEM supplemented with 1 % FBS then serum sustained for 24h prior to treatment with
serum-free media (1 % BSA) containing l OnM All or l OnM insulin used as a positive
control for 48h. Leptin content in culture media was then assayed using RIA. In the time
response studies, human adipose tissue was incubated with 1 OnM All or without All for
the indicated time intervals (3, 6, 12, 24 and 48h). The culture media were collected at the
indicated time points to measure leptin level. Data were expressed as leptin (ng/ml) per g
of tissue.
3T3-L l adipocytes: Optimal responses of secreted leptin and cyclooxygenase-derived
eicosanoids (6-keto PGF 1 a and PGE 2) to All treatment were established by determining
an optimal dose-response (lpM-l µM) and time-dependence (0, 3, 6, 12, 24, 36, 48, 72
and 96 h) curve. 3T3-L l adipose cells were cultured with serum-free media overnight in
100mm culture dishes or 6-well (35 mm) plates and then treated with All (Sigma
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Fig 1 . Experimental protocol using 3T3-L l adipose cells

Chemical Co., St. Louis, MO) in serum-free media. In dose-response studies, cells were
incubated for 48h with or without All. After 48h of treatment culture media were
collected to measure leptin and prostaglandin levels. To analyze time-response, culture
media of 3T3-Ll adipose cells treated with l OnM All or without All were used to
measure the levels of leptin, 6-keto PGF la and PGE 2 at the indicated time points. Cell
extracts were prepared for cellular protein contents. The levels of leptin and eicosanoids
were normalized to dish or cellular protein levels.
Experiment 2: we investigated the effect of prostaglandin biosynthesis inhibition by
indomethacin and aspirin on All-induced prostaglandin and leptin secretions in 3T3-Ll
adipocytes. Indomethacin and aspirin used in this study inhibit both COX-1 and COX-2.
Indomethacin is a time-dependent and reversible inhibitor whereas aspirin is time
dependent and irreversible (22). Inhibition of cyclooxygenase was conducted before All
treatment. Adipose cells were grown in 6-well plates and were preincubated with serum
free media in the absence or presence of various concentrations (1, 10, 50 or 100 µM) of
indomethacin and aspirin dissolved in appropriate solvent (0.2 % ethanol of final cone.)
for 6 h. After pretreatment with inhibitors, cells were treated with 1OnM All or vehicle
alone and maintained for 24h to investigate prostaglandin-mediated All regulation of
leptin secretion. In separate experiments, cells were simultaneously treated with
indomethacin and All. Cultured media were collected for determining leptin and
eicosanoid levels and cell extracts were prepared for cellular protein contents. The levels
of leptin and eicosanoids were normalized to dish or cellular protein contents.
Experiment 3 : we examined the effect of indomethacin on All regulation of leptin and 6keto PGF la secretions in the presence or absence of serum.
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Cells were incubated in either 1 0% FBS or 1 % BSA. All (l OnM), indomethacin (l OµM),
or All plus indomethacin treatments were carried out in both media for 24h and controls
were treated with vehicle only. The levels of leptin and 6-keto PGF 1 a secreted from both
media were measured by using RIA. The levels of leptin and eicosanoids were
normalized to cellular protein levels.

B. Methods
1 . Culture of human adipose tissue
Subcutaneous abdominal adipose tissue was taken from one subject, 26 yr of age,
undergoing elective cosmetic surgery. A sample was obtained in compliance with a
protocol approved by the Institutional Review Board for Human subjects and by the
Committee for Research Protocols at the University of Tennessee, Knoxville. This
subject was non-diabetic and non-obese with normal body mass index (BMI: 24.3 m!kg2)
and had no known metabolic abnormalities. Tissue was minced into 0. 1 -0.2 g pieces and
washed several times with Hank's medium to remove blood clots. Tissue fragments (-1
g/well) were primary cultured in DMEM supplemented with 1 % FBS media, antibiotics
(penicillin-I OOU/ml, streptomycin-I OOµg/ml and gentamicin-50µg/ml) for two days.
Human adipose tissue was incubated with serum-free media containing I % BSA for 24h
prior to treatment.
2. Culture of 3T3-LI adipose cells
3T3-Ll adipose cell lines are derived from mouse embryo (33). Cells were purchased
from the American Type Culture Collection (ATCC) and were grown in 1 00 mm dishes
or 6-well (35 mm) plates and cultured in DMEM supplemented with I 0% FBS and I %
50

penicillin/streptomycin (regular media); 3T3-Ll cells (-200,000 cells/100 mm dish;
50,000 cells/35mm dish) were plated at O days and grown for 3-4 days (confluence) . At
confluence, the media were supplemented with 250nM dexamethasone and 0. 5mM
isobutyl methylxanthine (MIX) for 72 h, after which cells were cultured with regular
media (29) . Differentiation was considered to be complete at 5-7 days after
postconfluence. All the studies were conducted in differentiated cells (-80-95 %). Prior to
any treatment with All or inhibitors, cells were incubated for 24h in serum free media
containing 1 % BSA.
3. Quantitation of leptin in the media
Leptin secreted in the media was determined by radioimmunoassay (RIA) that is a
subclass of competitive protein binding assay in which radiolabeled antigen (hormone)
complete with unlabeled antigen for sites on its antibody. The measurement of the
amount of radioactivity determines the amount of antigen present (30). The mouse leptin
RIA kit used in this study were purchased from Linco Research (St Charles, MO). 100 µI
of media collected was used and all samples were measured in duplicate. Leptin level
was corrected to mg of cellular protein contents or dish (well) for 3T3-Ll adipocytes and
g of tissue for human adipose tissue.
4. Prostaglandin assay
Culture media were treated with cold acid methanol solution (MeOH: Formic acid,
9 :l (v/v), pH 3.5). Prostaglandins were isolated by solid-phase extraction using an
octadecyl C 1 8 cartridge (Burdick & Jackson, Muskegon, MI) and eluted with 100 %
methanol. The methanol was evaporated under an atmosphere of nitrogen and the extracts
were resuspended with 250µ1 of O.l M PBSG (Phosphate Buffered Saline (0.9 %) with
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Gelatin (0.1 %), pH7.4). 100 µ1 ofresuspended solution was used for measuring contents
of each prostaglandin. The amount ofPGE 2 and 6-keto PGF la was assayed by RIA using
antiserum obtained from PerSeptive Diagnostics, Inc (Cambridge, MA). All standards
were purchased from Cayman Chemical (Ann Arbor, MI), and [ 3H] PGE 2 and [ 3H] 6-keto
PGF 1a were obtained from New England Nuclear (Boston, MA). All experiments were
repeated twice. Data are expressed as pg ofPGE2 and 6-keto PGF la per dish (well) or mg
ofcellular protein contents.
5 . Protein assay
The cellular protein contents were measured by Bradford method (32) that is a dye
binding assay. The acidic blue dye binds to primarily basic and aromatic amino acid
residues, especially arginine. A differential color change ofthe dye in response to various
protein concentrations is spectrophotometrically measured. Adipocytes were harvested by
scraping into 500µ1 of0.5M sucrose (pH 7.4), l mM dithioreitol, l mM EDTA and
1 OOmM phenylmethylsulfonyl fluoride (PMSF). Cell homogenates were sonicated for 5
sec and after l h ofultracentrifugation (12,000 x g) at 4 °C supematants were taken to
assay cellular protein contents. 25 µ1 of cell extracts was used and all samples were
assayed in duplicate.
6. Statistics
Data first were analyzed by one-way analysis of variance (ANOVA). When
significant F ratios were obtained, differences among different concentrations ofAll
were analyzed by Bonferroni test for multiple comparison (SAS, Cary, N.C.). The
significant differences between means with the same variances were evaluated by
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independent student' s t test. All values were expressed as mean ± SEM. Values of
P<0.05 were considered statistically significant.
IV. Results
Effect of All on leptin secretion in human adipose tissue
Previous studies showed that physiological concentration of All upregulates ob gene
transcription in human adipocytes (12). We first investigated the effect of All on leptin
secretion using culture of human adipose tissue. In good agreement with the All effect on
ob gene transcription, both All and insulin (used as a positive control) significantly

increased leptin secretion (Fig. 2). When human adipose tissue was exposed to All
(l OnM) for various lengths of time, leptin secretion progressively increased from 3h to
24h (Fig. 3). At 24 h, leptin secretion was stimulated by approximately 3. 5-fold
compared to controls (p<0.001). Similarly, All exhibited significant stimulation of leptin
secretion at 48h compared to controls. However, the decrease in AH-induced leptin level
between 24 h and 48h may result from leptin protein degradation. These results indicate
that physiological concentration of All increases leptin secretion after 24h in human
adipose tissue.
Effect of All on leptin and prostaglandin secretions in 3T3-Ll adipocytes
We investigated the dose and time-response effects of All on leptin and prostaglandin
secretions in 3T3-Ll adipose cells.
Leptin: Consistent with the increase in transcription rate of ob gene upon All

treatment (12), All at concentrations of 1 and l OnM significantly increased leptin
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secretion by 3T3-Ll adipose cells at 48h by 24 ± 9.8% and 57± 6.7%, respectively (Fig.
4). Significant effect of All on leptin secretion was observed at 1 2, 24, 36 and 48h by
l OnM of All treatment (Fig. 7) when leptin secretion was increased by approximately 3fold over control levels (p<0.01 ).
Protstaglandins: Similarly, prostaglandin secretions were significantly stimulated by

physiological doses of All (Fig. 5 and 6). Significant effect of All on 6-keto PGF l a
secretion (Fig. 5) was present at 48h of treatment with l nM and l OnM All (p<0.05). In
concordance, 3T3-Ll adipose cells cultured with l nM and l OnM All also increased
PGE2 secretion (Fig. 6) at 48h (p<0.05). All treatment ( 1 OnM) markedly stimulated 6keto PGF 1 a secretion from 3T3-Ll adipose cells within 24h and this stimulatory effect by
All was sustained for an additional 72h (Fig. 8). All significantly elevated PGE2
secretion within 24h and this level was maintained through 96h (Fig. 9). Consistent with
significant induction of prostaglandin secretions by All (1 OnM) after 24 h, All at
concentration of l nM significantly enhanced secretions of both prostaglandins after 24h
(data not shown).
All at physiological concentrations increased leptin and prostaglandin secretions
from 3T3-Ll adipose cells in a time-dependent manner. These results are consistent with
the previously reported induction of ob and PGHS gene expressions by All in murine
adipose cell lines ( 1 2, 1 5) and with induction of 6-keto PGF 1 a secretion by the presence of
All stimulus ( 1 4).
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Fig. 2 Effect of All on leptin secretion in human adipose tissue. Isolated human

adipose tissue was cultured in DMEM supplemented with 1 % FBS for 2 days and
maintained serum-free media for 24h before treatment. Cells were treated for 48h with
serum-free media supplemented with l OnM All, lOnM insulin and control adipose
tissue was treated with serum-free media containing 1 % BSA . Leptin concentration in
the culture media was measured by radioimmunoassay (RIA). Data shown are
expressed as mean ± SEM (n=3). Statistical differences from the corresponding control
treated and All or insulin-treated values are shown as p<0.05(*).
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Fig. 3 Time-response effect of All on leptin secretion in human adipose tissue.
Isolated human adipose tissue was maintained in DMEM supplemented with 1% FBS for
2 days and incubated with serum-free media for 24h before treatment. Adipose tissue was
treated for 48h with serum-free media supplemented with l OnM All or without All as
control. The culture media were collected at 3, 6, 1 2, 24, and 48h and leptin
concentration in the culture media was measured by RIA. Data shown are expressed as
mean ± SEM (n=3). Statistical differences from the corresponding control-treated and
All-treated values att he indicated time points are shown as p<0.01(*) and p<0.001(* *).
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Fig. 4 Dose effect of All on leptin secretion in 3T3-Ll adipose cells. Fully
differentiated adipocytes were incubated with serum-free media containing
graded concentrations of All (l pM-l µM) or without All as control for 48h.
Leptin secreted in medium was measured by using RIA at the specified time.
Results are expressed as mean ± SEM (n=9). Data shown are analyzed by
ANOVA and Bonferroni multiple-comparison procedure. The values with
different letters are significantly different at p<0.05.
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Fig. 5 Dose effect of All on 6-keto PGF1 a secretion in 3T3-Ll adipose cells.

Differentiated 3T3-Ll adipocytes were incubated with serum-free media supplemented
with increasing concentrations (1pM-1 µM) of All or without All for 48 h. The amount
of 6-keto PGF l a, the stable degradation product of PGiz, in the culture media was
measured by RIA. Data are expressed as mean ± SEM (n=3). Results are analyzed by
ANOVA and Bonferroni multiple comparison procedure. The values with different
letters are significantly different at p<0.05.
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Fig. 6 Dose effect of All on PGE 2 secretion in 3T3-Ll adipose cells. Differentiated
3T3-L l adipocytes were incubated with serum-free media supplemented with
increasing concentrations (lpM- l µM) of All or without All for 48h. PGE2
concentration in the culture media was measured by RIA. Data are expressed as mean
± SEM (n=3). Results are analyzed by ANOVA and Bonferroni multiple comparison
procedure. The values with different letters are significantly different at p<0.05 .
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Fig. 7 Time-response effect of All on leptin secretion in 3T3-Ll adipose cells.
Differentiated adipose cells were incubated for 24h with serum-free media
supplemented with l OnM All and culture media were collected at 0, 3, 6, 12, 24, 36
and 48h. The amount of leptin secreted in the culture media was assessed by RIA.
Data shown are expressed as mean ± SEM (n=3). Statistical differences from the
basal concentration of leptin at time zero for 3T3-Ll adipose cells are shown as
p<0.01(*).
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Fig. 8 Time-response effect of All on 6-keto PGF 1 a secretion in 3T3-Ll adipose
cells. Differentiated adipose cells were incubated for 96h with serum-free media

containing l OnM All or without All and the culture media were collected at 0, 3, 6, 12,
24, 48, 72 and 96h. The amount of 6-keto PGF l a, a stable derivative of PGh, in the
culture media was assayed by RIA and normalized to milligram of cellular protein
values. Data shown are expressed as mean ± SEM (n=5-6). Statistical differences
between control-treated and All-treated values at the indicated time points are shown as
p<0.01(*) and p<0.0001(* *).
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Fig. 9 Time-response effect of All on PGE 2 secretion in 3T3-Ll adipose cells.

Differentiated adipose cells were maintained in serum-free media with l OnM All or
without All for 96h and cultured media were collected at 0, 3, 6, 12, 24, 48, 72 and 96h.
PGE2 concentration in the culture media was measured by RIA and corrected to
milligram of cellular proteins. Data shown are expressed as mean ± SEM (n=5-6).
Statistical differences between the corresponding control-treated and All-treated values
at the indicated each time points are shown as p<0.05 (*) and p<0.001(* *).
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Effect of indomethacin and aspirin on All-induced prostaglandin and leptin secretions in
3T3-Ll adipocytes
To further investigate the mechanisms through which All increases leptin secretion
in adipocytes, effect of prostaglandin synthesis inhibition by indomethacin and aspirin on
All-induced prostaglandin and leptin secretions was conducted.
Prostaglandins: As anticipated, pretreatment (6h prior to l OnM All of treatment) of

indomethacin (Fig. 10) and aspirin (Fig. 11) at concentrations of 1, 10, 50 and 1OOµM
significantly inhibited both basal and All-induced 6-keto PGF la secretions in a dose
response manner (p<0.05). The concentration of 1 OµM of indomethacin maximally
reduced 6-keto PGF la synthesis in both vehicle and All-treated cells by approximately
43% and 58%, respectively (Fig. 10). Similarly, aspirin at a concentration of l OµM
maximally inhibited basal and All-induced 6-keto PGF la levels by ----45 and 65%,
respectively (Fig. 11). These similar reductions (----35-60%) in basal and All-induced 6keto PGF la levels were also noted when either inhibitor was added concomitantly with
All for 24h (data not shown). However, both inhibitors decreased basal and All-induced
PGE2 secretions to a lesser extent (----10-30% reduction) compared to those observed with
6-keto PGF la (Fig. 1 2 and 1 3). This differential inhibition of 6-keto PGF la versus PGE2
by indomethacin and aspirin was unexpected.
Leptin : The effects of maximal inhibitory concentration (l OµM) of indomethacin

(Fig. 14) and aspirin (Fig. 15) on basal as well as All-stimulated leptin secretions were
evaluated. Inhibition of All-induced prostaglandin synthesis by 6h of pretreatment with
l OµM indomethacin did not modify basal or All-induced leptin secretion (Fig. 14).
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Similarly, aspirin did not alter basal or All-induced leptin level. Consistent with these
results, the inhibitory effect of indomethacin and aspirin when added simultaneously with
All for 24h did not affect basal or All-increased leptin secretion (Fig. 15).
Effect of indomethacin on All-induced prostaglandin and leptin secretions from 3T3-Ll
adipocytes in the presence or absence of serum
To confirm the effect of indomethacin on All-induced leptin secretion, we used 10%
fetal bovine serum (FBS) as a positive control and 1% bovine serum albumin (BSA) of
culture media supplemented with All (1 OnM), indomethacin (1 OµM), and All (1 OnM)
plus indomethacin (1 OµM). FBS was used to elicit maximal induction of prostaglandins
as previous studies have demonstrated that FBS stimulates prostaglandin synthesis in
adipocytes (37).
Prostaglandins: We have examined the inhibitory effect of 6-keto PGF1a secretion
by indomethacin. An inhibitory effect of indomethacin (l OµM) for 24h on basal and All
induced 6-keto PGF I a secretions in both media (Fig 16). Indomethacin treatment
significantly reduced basal and All-induced 6-keto PGF 1 a secretions by approximately
66% and 79%, respectively in 10% FBS media. Similarly, indomethacin significantly
blocked basal and All-induced 6-keto PGF1a secretions in 1 % BSA media. Accordingly,
we confirmed an inhibitory effect of indomethacin on basal and All-induced 6-keto
PGF 1 a secretions from 3T3-Ll adipose cells in both the presence and absence of serum.
Interestingly, compared to 1% BSA media, higher inhibitory effect of indomethacin on
basal and All-induced 6-keto PGF1 a levels were observed in 10% FBS media at 24h. A
possible explanation for lower basal and All-induced 6-keto PGF 1 a secretions in 10%
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FBS media by indomethacin is the high cellular protein contents in FBS-treated cells,
resulting in lower prostaglandin/protein level in FBS-treated cells versus BSA-treated
cells; these data also were normalized per well (Appendix, Fig. 1). Along this possibility,
we have examined the levels of 6-keto PGF la and PGE2 in the presence or absence of
serum with or without 3T3-Ll adipose cells; these data were corrected to well or total
cellular proteins (Appendix, Fig 3-5). It seems clear that lower basal and All-induced 6keto PGF 1 a levels in FBS media is due to increased total cellular protein levels in the
presence of serum.

Leptin: As seen with prostaglandin inhibitor pretreatment results, indomethacin
treatment (Fig. 17) did not affect the basal and All-induced leptin secretions in 10 % FBS
media. Similarly, in the 1% BSA media, inhibition of prostaglandin synthesis by
indomethacin did not modify basal and All-induced leptin secretions. Additionally,
compared to those in BSA-treated cells, similar results of lower basal and All-induced
leptin levels were obtained in FBS-treated cells; these data also were normalized on a per
well basis (Appendix, Fig. 2).

V. Discussion & Conclusion
In this study, we investigated the biochemical mechanisms by which All regulates
leptin secretion in adipocytes. Previous investigations have reported that AIi may function
as an adipogenic factor in adipocyte growth and development through interaction with its
receptors (4, 12, 14). Further, we have demonstrated that All increases leptin expression in
. cultured adipocytes (12). These cumulative findings suggest a strong link between All and

65

8000

.s
e

0..

O Control

ri! l OnM All

d

6000

0..

b

] 4000

....
�

ab

a

2000

0
w/o Inhibitor

1 uM Indo

l OuM Indo

50uM Indo

l OOuM Indo

Fig. 1 0 Effect of indometbacin in All-induced 6-keto PGF ta secretion in 3T3-Ll adipose
cells. Differentiated adipose cells were preincubated with serum-free media supplemented

with vehicle (0.2 % ethanol), 1 µM, 1OµM, 50µM or 1OOµM indomethacin, an inhibitor of
prostaglandin synthesis, for 6h. After pretreatment cells were incubated for 24h with serum
free media supplemented with 1OnM All or vehicle alone. Treated cells were harvested in
0.5M sucrose buffer and the culture media were collected. The amount of 6-keto PGF 1 a
secreted in the culture media was assayed by RIA and normalized to milligram of total
cellular proteins. Results are expressed as mean ± SEM (n=5-6). Statistical differences
between vehicle or indomethacin-treated values and All or All plus indomethacin -treated
values are shown; between vehicle-treated and indomethacin-treated values; between All
treated and . All plus indomethacin-treated values. The values with different letters are
significantly different at p<0.05.
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Fig. 1 1 Effect of aspirin on All-induced 6-keto PGF Ia secretion in 3T3-Ll adipose
cells. Differentiated adipose cells were pretreated with serum-free media supplemented

with vehicle (0.2 % ethanol), 1 OµM, 50µM or 1OOµM aspirin for 6h and then incubated
for 24h with 1OnM All or vehicle alone. Treated cells were harvested in 0.5M sucrose
buffer and the culture media were collected. 6-keto PGF

la

level secreted in the culture

media was assayed by RIA and normalized to milligram of total cellular proteins.
Results are expressed as mean ± SEM (n=5-6). Statistical differences between vehicle
or aspirin-treated values and AII or All plus aspirin-treated values are shown; between
vehicle-treated and aspirin-treated values; between AH-treated and All plus aspirin
treated values. The values with different letters are significantly different at p<0.05.
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Fig. 12 Effect of indomethacin on All-induced PGE2 secretion in 3T3-Ll adipose
cells. Differentiated adipose cells were pretreated with serum-free media in the

presence of vehicle (0.2% ethanol), 1µM, 1 OµM, 50µM or 1OOµM indomethacin for
6h. After pretreatment cells were cultured for 24h with serum-free media
supplemented with 1OnM All or vehicle alone. Treated cells were harvested in 0.5M
sucrose buffer and the culture media were collected. The amount of PGE2 secreted in
culture media was measured by RIA and corrected to milligram of total cellular
proteins. Results are expressed as mean ± SEM (n=5-6). Statistical differences
between vehicle or indomethacin-treated values and All or All plus indomethacin
treated values are shown; between vehicle-treated and indomethacin-treated values;
between All-treated and All plus indomethacin-treated values.
different letters are significantly different at p<0.05.
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Fig. 1 3 Effect of aspirin on All-induced PGE 2 secretion in 3T3-Ll adipose cells.
Fully differentiated adipose cells were pretreated with serum-free media containing
vehicle (0.2% ethanol), 1 OµM, 50µM or 1OOµM aspirin for 6h and then incubated for
24h with l OnM All or vehicle alone. Treated cells were harvested in 0.5M sucrose
buffer and culture media were collected after 24-h treatment. The concentration of
PGE2 secreted in the culture media was measured by RIA and normalized to
milligram of cellular proteins. Results are expressed as mean ± SEM (n=5-6).
Statistical differences between vehicle or aspirin-treated values and All or All plus
aspirin-treated values are shown; between vehicle-treated and aspirin-treated values;
between All-treated and All plus aspirin-treated values. The values with different
letters are significantly different at p<0.05.
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Fig. 14 Effect of indomethacin & aspirin pretreatment on All-induced leptin
secretion in 3T3-Ll adipose cells. Fully differentiated adipose cells were pretreated

with serum-free media (1% BSA) supplemented with vehicle (0.2 % ethanol), l OµM
indomethacin or 1 OµM aspirin for 6h and then maintained for 24h with vehicle alone or
l OnM AIL After treatment, treated cells were harvested in 0.5M sucrose buffer and the
culture media were collected. The amount of leptin secreted in the culture media was
measured by RIA and normalized to cellular protein values. Results are expressed as
mean ± SEM (n=5-6). Statistical differences between vehicle or indomethacin or aspirin
-treated values and All or All plus indomethacin or All plus aspirin-treated values are
shown; between vehicle-treated and indomethacin or aspirin-treated values; between
All-treated and All plus indomethacin or aspirin-treated values. The values with
different letters are significantly different at p<0.05.
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Fig. 1 5 Effect of indomethacin & aspirin on All-induced leptin secretion in 3T3-Ll
adipose cells. Fully differentiated adipose cells were treated with serum-free media (1%

BSA) supplemented with vehicle (0.2 % ethanol), 1OnM All, indomethacin (10, 50,
1OOµM), aspirin (10, 50, 1OOµM), or AI� plus indomethacin or aspirin for 24h. After
treatment, treated cells were harvested in 0.5M sucrose buffer and the culture media were
collected. Leptin level secreted in the culture media was measured by RIA and normalized
to cellular protein values. Results are expressed as mean ± SEM (n=5-6). Statistical
differences between vehicle or indomethacin or aspirin-treated values and All or All plus
indomethacin or All plus aspirin-treated values are shown; between vehicle-treated and
indomethacin or aspirin-treated values; between All-treated and All plus indomethacin or
aspirin-treated values. The values with different letters are significantly different at p<0.05.
71

• Control

D AIi

El All plus Inoorrethacin

� lnootrethacin
50000

d

e

] 40000
C.

� 30000
C.

- 20000

.: 10000

0

10 %FRS

1% BSA

Fig. 1 6 Effect of indomethacin on All-induced 6-keto PGF

ta

secretion by 3T3-Ll

adipose cells in the presence or absence of serum. Fully differentiated adipose cells

were cultured in 10% FBS or 1% BSA media before treatment. Cells were incubated with
both media supplemented with vehicle (0.2% ethanol), 1OnM All, 1OµM indomethacin or
All (1OnM) plus indomethacin (1 Oµ M) for 24h. Treated cells were harvested in 0.5M
sucrose buffer and the culture media were collected. The amount of 6-keto PGF

1a

was

measured in both media by RIA and normalized to milligram of total protein values.
Results are expressed as mean ± SEM (n=5). Statistical differences between vehicle or
indomethacin-treated values and All or All plus indomethacin-treated values are shown;
between vehicle-treated and indomethacin-treated values; between All-treated and All
plus indomethacin-treated values. The values with different letters are significantly
different at p<0.05.
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Fig. 1 7 Effect of indomethacin on All-induced leptin secretion by 3T3-Ll adipose
cells in the presence or absence of serum. Fully differentiated adipose cells were

cultured with 10% FBS or 1% BSA media before treatment. Cells were incubated with
both media containing vehicle (0.2% ethanol) as control, 1 OnM All, 1OµM
indomethacin, or All (1OnM) plus indomethacin (1OµM) for 24h. Treated cells were
harvested in 0.5M sucrose buffer and the culture media were collected. Leptin level
was measured in both media by RIA and normalized to cellular protein values. Results
are expressed as mean ± SEM (n=5). Statistical differences between vehicle or
indomethacin-treated values and All or All plus indomethacin -treated values are
shown; between vehicle-treated and indomethacin-treated values; between All-treated
and All plus indomethacin -treated values. The values with different letters are
significantly different at p<0.05.
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leptin in the adipogenic functions of AIL Our results clearly demonstrate that All
increases leptin secretion from human and 3T3-Ll adipose cells in a time-responsive
manner. Dose response analysis shows that All at physiological concentrations stimulates
leptin secretion from human and 3T3-Ll adipose cells. Accordingly, our results support
that All may play a role as a regulator of leptin in adipocyte metabolism. To date, the
signaling mechanisms by which All increases leptin secretion and promotes adiposity
remain to be elucidated. Previous study by Darimont has suggested that prostacyclin
synthesized by mature adipocytes functions as a mediator of All action on adipocyte
growth ( 14). Additionally, preliminary research has shown that PGE2 and PGI2 mainly
produced from rodent and human adipocytes function as hypertrophic as well as
hyperplastic effectors in adipocyte differentiation and development through
paracrine/autocrine effects (11, 14, 24-25). Recent research has demonstrated that PGE2
functions tumor vascularization thus leading to tumor growth, suggesting that
prostaglandin may act as an important paracrine effector in angiogenesis of adipocyte (3).
Consistent with previous reports (14-15), our study demonstrates that All at
physiological concentrations produces time-dependent stimulation of 6-keto PGF 1 a and
PGE2 secretions in adipose cells. These results suggest that these prostaglandins may be
potential candidates for mediating the effect of All on leptin secretion. Accordingly, we
investigated whether All enhances leptin stimulation via a prostaglandin-mediated
mechanism. As expected, both inhibitors significantly decreased basal and AII-'induced 6keto PGF l a secretions from adipose cells. However, both indomethacin and aspirin
showed less effective inhibitory effects on basal and All-induced PGE2 secretions from
3T3-Ll adipose cells. The slight blockades of basal and All-induced PGE2 secretions by
74

both inhibitors may possibly be explained by alternative or additional pathway (COX-3)
of prostaglandin biosynthesis in adipocytes (36).
In the subsequent experiments, cyclooxygenase inhibition by indomethacin and
aspirin did not modify basal or All-induced leptin releases from 3T3-Ll adipose cells.
Results from this study clearly demonstrate that All stimulates leptin secretion but that
this effect is not mediated via prostaglandin. In addition, coupled with inhibitor
pretreatment, data from the presence and absence serum experiments also show that All
regulates leptin secretion in adipocytes via a prostaglandin-independent mechanism.
Additionally, indomethacin may play a critical role as a ligand of adipogenic
transcription factor, PPARy, rather than as an inhibitor in prostaglandin biosynthesis.
Recent research has shown that indomethacin at high concentrations (µM range) binds
and activates PPARy, thus inducing adipogenesis, but at low concentrations (nM range),
it exhibits an inhibitory effect on prostaglandin synthesis (26). More recently, a study by
Sinha et al has illustrated that indomethacin displays an inhibitory effect on leptin
secretion at concentration at which it activates PPARy in adipocytes (23). In the present
study, high concentrations of indomethacin which induced reduction of prostaglandin
secretion did not modify leptin secretion, suggesting that it may predominately affect
COX inhibition versus PPARy activation under the present experiment conditions. Also,
indomethacin plu_s All treatment increases leptin secretion in adipocytes due to All effect
on leptin secretion and results also observed with aspirin.
In summary, our data indicate that All increases leptin secretion from adipocytes via
a prostaglandin-independent mechanism, suggesting that alternative or additional
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mechanisms are involved in All-induced leptin secretion. In addition to stimulation of
FAS and triglyceride synthesis by All, this hormone also increases leptin secretion. This
study provides therefore a potential mechanism by which All may regulate adiposity.
This understanding of the RAS and All paracrine effects in adipocytes may provide
insights into the development of new therapeutic approaches to prevent obesity and its
associated disorders.
Further work is required to characterize the mechanism of All regulation of the ob
gene transcription and identify mechanism of All signaling in adipocytes leading to
regulation of fatty acid synthesis and leptin secretion.
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Previous research has shown that calcium ionophore A23 187 and serum elicit a
release of arachidonic acid, leading to an increase in prostaglandin formation. In this
regard, we used fetal bovine serum (FBS, 10%) as a positive control to stimulate
prostaglandin synthesis. As unexpected, we observed higher inhibitory effect of
indomethacin on basal and All-induced 6-keto PGF 1a levels in FBS-treated cells. One
possibility is that the high cellular protein contents in FBS media may contribute to lower
basal and All-induced 6-keto PGF

la

levels in FBS-treated cells compared to those in

bovine serum albumin (BSA, 1 %)-treated cells. To test this possibility, we measured the
levels of 6-keto PGFl a and PGE2 in the presence or absence of serum with or without
3T3-Ll adipose cells; all data were also corrected to well or total cellular protein
contents. These results clearly demonstrate that the lower 6-keto PGF

la

and PGE2 levels

in FBS stimulation is due to increased total cellular protein levels in the presence of
serum.
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Fig. 1 Effect of indomethacin on All-induced 6-keto PGF Ia secretion by 3T3-Ll
adipose cells in the presence or absence of serum. Fully differentiated adipose cells

were cultured in 1 0% FBS or 1 % BSA media before treatment. Cells were incubated
with both media containing vehicle (0.2% ethanol), 1 OnM All, 1 OµM indomethacin or
All (1 OnM) plus indomethacin ( 1 OµM) for 24 h. Treated cells were harvested in 0.5M
sucrose buffer and the culture media were collected. The amount of 6-keto PGF 1 a was
measured in both media by RIA and normalized to well. Results are expressed as mean
± SEM (n=5). Statistical differences between vehicle or indomethacin-treated values
and All or All plus indomethacin-treated values are shown; between vehicle-treated
and indomethacin-treated values; between All-treated and All plus indomethacin
treated values. The values with different letters are significantly different at p<0.05.
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Fig. 2 Effect of indomethacin on All-induced leptin secretion by 3T3-Ll adipose
cells in the presence or absence of serum. Fully differentiated adipose cells were

cultured with 10% FBS or 1% BSA media before treatment. Cells were incubated
with both media containing vehicle (0.2% ethanol) as control, 1OnM AIi, 1OµM
indomethacin, or All (l OnM) plus indomethacin (l OµM) for 24 h. Treated cells were
harvested in 0.5M sucrose buffer and the culture media were collected. Leptin level
was measured in both media by RIA and normalized to well. Results are expressed
as mean ± SEM (n=5). Statistical differences between vehicle or indomethacin
treated values and AIi or All plus indomethain-treated values are shown; between
vehicle-treated and indomethacin-treated values; between AIi-treated and All plus
indomethacin-treated values. The values with different letters are significantly
different each other at p<0.05.
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Fig. 3 Measurement of exogenous 6-keto PGF ta level in the presence or absence of
serum. Differentiated adipose cells were cultured in DMEM containing 10% PBS or

1% B SA and incubated for 24 h with [3H] 6-keto PGF

I a,

which was directly added in

both media with or without cells. After 24-h treatment culture media were collected and
prostaglandins were isolated by solid-phase extraction using an octadecyl C 1 8 cartridge
and eluted with 100% methanol (2ml) twice. The radioactivity of eluted prostaglandins
(2ml) was measured using � counter. No significant differences between 10% FBS
treated and 1% B SA-treated values with or without cells were shown.
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Fig. 4 Measurement of 6-keto PGF 1a level in the presence or absence of serum with or without 3T3-Ll adipose cells.

Differentiated adipose cells were incubated for 24 h in DMEM containing 1 0% FBS or 1 % BSA. After 24-h culture cells
were harvested in 0.5M sucrose buffer and the culture media were collected. The amount of 6-keto PGF

Ia was

measured

in both media by RIA and normalized per well (A) or milligram of total cellular proteins (B). Data are expressed as mean
± SEM (n=6). Statistical differences between 1 0% FBS and 1 % BSA-treated values. The values with different letters are
significantly different each other at p<0.05 .
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Fig. 5 Measurement of PGE 2 level in the presence or absence of serum with or without 3T3-Ll adipose cells.
Differentiated adipose cells were incubated for 24 h in DMEM containing 1 0% FBS or 1 % BSA. After 24-h culture
cells were harvested in 0.5mM sucrose buffer and the culture media were collected. PGE2 concentration was
measured in both media by RIA and normalized per well (A) or milligram of total cellular proteins (B). Data are
expressed as mean ± SEM (n=6). Statistical differences between 1 0% FBS and 1 % BSA-treated values. The values
with different letters are significantly different at p<0.05 .
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